As the glaucoma treatment landscape advances—with minimally invasive options increasingly integrated into clinical practice—managing early-stage disease has become a critical therapeutic window. Timely, evidence-based intervention at this stage can help preserve vision and prevent lifelong disability.

In recent years, innovations in both procedural and pharmacologic therapies have transformed how clinicians approach early-stage glaucoma. This consensus statement—developed by leading glaucoma specialists and comprehensive ophthalmologists—draws from current survey data, clinical experience, and real-world practice patterns. It provides a harmonized view of how SLT and SR drug delivery systems can function as complementary tools in the modern treatment algorithm.

Grant Support Statement
This activity is supported by unrestricted educational grants from AbbVie, Alcon, and Glaukos. Content supplied by The Fundingsland Group.

Accreditation Statement

The Fundingsland Group, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The Fundingsland Group, LLC designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.